Phase II study of dovitinib in first line metastatic or (nonresectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03

被引：1
|
作者：
Garcia-Donas, Jesus
Hernando Polo, Susana
Guix, Marta
Climent Duran, Miguel Angel
Mendez Vidal, Maria Jose
Jimenez, Paula
Leon Mateos, Luis
Francisco Rodriguez-Moreno, Juan
Moreno, Fernando
Segura, Eduardo
Duran, Ignacio
Macia, Sonia
Arranz Arija, Jose Angel
Vazquez-Estevez, Sergio
Javier Perez, Francisco
Lainez, Nuria
Castellano, Daniel E.
机构：
[1] Ctr Integral Oncol Clara Campal, Madrid, Spain
[2] Hosp Univ Fdn Alcorcon, Alcorcon, Spain
[3] Univ Hosp Mar IMIM, Barcelona, Spain
[4] Fdn Inst Valenciano Oncol, Valencia, Spain
[5] Hosp Reina Sofia, Cordoba, Spain
[6] Hosp Univ Cent Asturias, Oviedo, Spain
[7] Complejo Hosp Univ Santiago, Oncol Serv, Santiago, Spain
[8] Hosp Clin Univ San Carlos, Madrid, Spain
[9] Novartis, Madrid, Spain
[10] Hosp Univ Virgen del Rocio, Seville, Spain
[11] Hosp Gen Elda, Elda, Spain
[12] Hosp Gen Gregorio Maranon, Madrid, Spain
[13] Hosp Univ Lucus Augusti, Lugo, Spain
[14] Inst Catala Oncol, Clin Res Unit, Lhospitalet De Llobregat, Spain
[15] Complejo Hosp Navarra, Pamplona, Spain
[16] Hosp Univ 12 Octubre, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4587
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of dovitinib in first-line metastatic or nonresectable primary adrenocortical carcinoma (ACC): SOGUG study 2011-03
    Jimenez, Paula
    Guix, Marta
    Lainez Milagro, Nuria
    Leon Mateos, Luis
    Mendez Vidal, Maria Jose
    Climent Duran, Miguel Angel
    Garcia-Donas, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC) - SOGUG study 2011-03
    Garcia-Donas, J.
    Hernando, S.
    Guix, M.
    Climent, M.
    Mendez, M. J.
    Jimenez, P.
    Lainez, N.
    Leon, L.
    Castellano, D.
    Moreno, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S659 - S659
  • [3] PHASE II STUDY OF DOVITINIB IN FIRST LINE METASTATIC OR (NON RESECTABLE PRIMARY) ADRENOCORTICAL CARCINOMA (ACC). SOGUG STUDY 2011-03
    Hernando, S.
    Garcia-Donas, J.
    Climent, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 293 - 293
  • [4] Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03
    Garcia-Donas, Jesuis
    Hernando Polo, Susana
    Guix, Marta
    Climent Duran, Miguel Angel
    Jose Mendez-Vidal, Maria
    Jimenez-Fonseca, Paula
    Lainez, Nuria
    Leon Mateos, Luis
    Moreno, Fernando
    Segura Gonzalez, Eduardo Raul
    Duran, Ignacio
    Javier Perez, Francisco
    Francisco Rodriguez-Moreno, Juan
    Macia, Sonia
    Vazquez-Estevez, Sergio
    Angel Arranz, Jose
    Castellano, Daniel E.
    Rodriguez de Antona, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma (ACC).
    Dillon, Patrick Michael
    Petroni, Gina R.
    Moskaluk, Chris
    Fracasso, Paula M.
    Douvas, Michael G.
    Perez, Jose Ricardo
    Varhegyi, Nikole
    Zaja-Milatovic, Snjezana
    Thomas, Christopher Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Preliminary results from a phase II study of nivolumab for patients with metastatic adrenocortical carcinoma (ACC).
    Cavalcante, Ludimila
    Carneiro, Benedito A.
    Costa, Ricardo Lima Barros
    Chae, Young Kwang
    Rademaker, Alfred
    Giles, Francis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [7] A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
    Dillon, Patrick M.
    Petroni, Gina R.
    Horton, Bethany J.
    Moskaluk, Christopher A.
    Fracasso, Paula M.
    Douvas, Michael G.
    Varhegyi, Nikole
    Zaja-Milatovic, Snjezana
    Thomas, Christopher Y.
    CLINICAL CANCER RESEARCH, 2017, 23 (15) : 4138 - 4145
  • [8] Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma
    Glazer, Evan S.
    Piccirillo, Mauro
    Albino, Vittorio
    Di Giacomo, Raimondo
    Palaia, Raffaele
    Mastro, Angelo A.
    Beneduce, Gerardo
    Castello, Giuseppe
    De Rosa, Vincenzo
    Petrillo, Antonella
    Ascierto, Paolo A.
    Curley, Steven A.
    Izzo, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2220 - 2226
  • [9] Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma
    Lagana, M.
    Grisanti, S.
    Ambrosini, R.
    Cosentini, D.
    Abate, A.
    Zamparini, M.
    Ferrari, V. D.
    Gianoncelli, A.
    Turla, A.
    Canu, L.
    Terzolo, M.
    Tiberio, G. A. M.
    Sigala, S.
    Berruti, A.
    ESMO OPEN, 2022, 7 (02)
  • [10] Phase II study of dovitinib (TKI258) in patients with progressive metastatic adenoid cystic carcinoma
    Dillon, Patrick Michael
    Moskaluk, Chris
    Fracasso, Paula M.
    Petroni, Gina R.
    Thomas, Christopher Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345